Xenetic Biosciences, Inc. · NASDAQ:XBIO
Xenetic Biosciences — Merger or Acquisition (September 2026)
25 slides from Xenetic Biosciences's merger presentation, Sep 16, 2026
Slide 1: Advancing NET-Targeted Therapies for Immune-Driven Diseases and Cancer
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer INVESTOR PRESENTATION SEPTEMBER 2026
Slide 2: Forward-looking statements
2 This communication contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 , including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed transac
Slide 3: Pioneering Breakthrough NET-Targeted Therapies
3 Pioneering Breakthrough NET - Targeted Therapies to Transform the Treatment Paradigm of Immune - Driven Diseases and Cancer Positive clinical outcomes with no adverse events across 80+ compassionate use cases in patients with sepsis, autoimmune disease and cancer treated with NucleoCapture® and DN
Slide 4: Two Complementary Technologies. One Target.
4 DNase Blood Purification Device for Circulating NETs Removes NETs directly from circulation via extracorporeal blood purification Targeting high levels of circulating NETs in the blood Pharmacological / Enzymatic for Tissue Based NETs Degrades NETs within solid tissue via enzymatic digestion of th
Slide 5: Excessive and Persistent NETs Are Convergent Upstream Driver of Inflammation
5 Excessive and Persistent NETs Are Convergent Upstream Driver of Inflammation, Tissue Injury, Immune Dysregulation and Treatment Resistance Neutrophil extracellular traps (NETs) are web - like structures composed of DNA, histones and antimicrobial proteins released by activated neutrophils to trap
Slide 6: Advancing Two NET-Targeted Platforms Across Immune-Driven Diseases and Cancer
6 NucleoCapture® Sepsis in Combination with SoC Systemic Lupus Erythematosus (SLE) in Combination with SoC Liver Graft Perfusion in Combination with OrganOx Metra Device Large B - Cell Lymphoma in Combination with anti - CD - 19 CAR T cells DNase THERAPEUTIC BLOOD PURIFICATION DEVICE PIPELINE SYSTEM
Slide 7: NucleoCapture: FDA-Designated Breakthrough Treatment for Sepsis
7 NucleoCapture ®: FDA - Designated Breakthrough Treatment for Sepsis Proprietary therapeutic blood purification device that physically bind to and remove NETs from blood circulation without affecting neutrophils defensive functions Ongoing pivotal multicenter study, up to 350 patients with sepsis a
Slide 8: Demonstrated 100% Day Survival with Reductions in Circulating NET Levels in Sepsis
8 Demonstrated 100% 7 - Day Survival with Rapid, Repeated Reductions in Circulating NET Levels in Sepsis Patients Reduction in Key Biomarkers Before After Before After Before After Before After Circulating NET Level, ng/mL n=10 Treatment Treatment Treatment Reduction in Circulating Net Levels Circul
Slide 9: Ongoing Pivotal Multicenter Study for Treatment of Sepsis
9 Ongoing Pivotal Multicenter Study for Treatment of Sepsis and Respiratory Failure Study Design Number of Subjects: up to 350 Randomized: 1:1 Treatment: SoC or SoC + NucleoCapture ® Primary Effectiveness Endpoint: Composite outcome evaluated using win ratio methodology: • All - cause mortality thro
Slide 10: NucleoCapture: FDA-Designated Breakthrough Treatment for SLE
10 After the Course of Procedures Before Improvement in Key Indicator Lupus Disease Activity 1 8.0 [4; 12] 17.5 [10; 25] SLEDAI, Me [25th; 75th percentiles] Lupus QoL 76.6 [51.6; 92.2] 57.8 [42.2; 67.2] Physical Health ( ↑ = Improvement) 87.5 [66.7; 91.7] 58.3 [41.7; 70.8] Pain ( ↑ = Improvement) 75
Slide 11: NucleoCapture: Restoring Viability in Donor Organs During Ex Vivo Machine Perfusion
11 NucleoCapture ®: Restoring Viability in Donor Organs During Ex Vivo Machine Perfusion Liver Revitalization Before After 6 hour Perfusion ~84% Reduction in Circulating NETs 13.54 ± 8.53 to 2.21 ± 0.69 µg/mL From hour 1 to hour 12 of NMP ~67% Reduction in Lactate 13.54 ± 8.53 to 2.21 ± 0.69 µg/mL F
Slide 12: DNase for LBCL: Overcoming Tumor Immune Evasion
12 DNase for LBCL: Overcoming Tumor Immune Evasion EGFR CAR T EGFR CAR T plus DNase Metastatic melanoma node; Green and yellow = NETosis area DNase driven survival benefit in mouse model of human lymphoma ( NSG/Raji) Removal of barrier to CAR T cells Deoxyribonuclease I (DNase) is a human endonuclea
Slide 13: Leadership and Development Team
13 Leadership and Development Team James Ladtkow BSME, MBA Chief Executive Officer Andrew Aswani, MD PhD MRCP FRCA EDIC FFICM Chief Medical Officer and SAB Chairman Elisabeth Barabash, BS, MS Chief Clinical Operations Alexey Stepanov, II, MS, PhD Head of Immunooncology Paul Rowden, BS, MS Head of Qu
Slide 14: Upcoming Value Driving Milestones
14 Upcoming Value Driving Milestones NucleoCapture ® SLE Program NucleoCapture ® Liver Transplantation Program DNase Large B - Cell Lymphoma Program Q4 2027 Q4 2027 Q4 2027 Q2 2028 First Interim Analysis (100 patients) Exclusive Distribution Agreement EU Regulatory Submission CE Certification and EU
Slide 15: Positioned to Lead the Emerging Field of NET-Targeted Therapeutics
15 Positioned to Lead the Emerging Field of NET - Targeted Therapeutics Building an integrated therapeutic portfolio around NETs, an increasingly recognized driver of disease progression across immune - driven diseases and cancer Four prioritized programs spanning sepsis, SLE, liver transplantation
Slide 16: Transaction Highlights
16 Transaction Highlights Proposed Transaction is Expected to Close in the Fourth Quarter of 2026 1 Santersus will become a wholly owned subsidiary of Xenetic and will continue as the operating business of the combined company . Combined company is expected to trade on Nasdaq under the ticker symbol
Slide 17: Thank you!
Advancing NET - Targeted Therapies for Immune - Driven Diseases and Cancer Thank you!
Slide 18: Appendix
| Appendix
Slide 19: NucleoCapture: Breakthrough Treatment for SLE
19 NucleoCapture ® is designed to selectively remove circulating NETs, potentially reducing the autoantigen and inflammatory burden without suppressing immune cells. NucleoCapture ®: Breakthrough Treatment for SLE Excessive NET formation and impaired clearance expose autoantigens, amplify type I int
Slide 20: SLE: Significant Reduction in Disease Activity After 3 NucleoCapture Treatments
20 SLE: Significant Reduction in SLE Disease Activity in Retrospective Analysis After 3 NucleoCapture® Treatments Before Indicator 8.0 [4; 12] 17.5 [10; 25] SLEDAI, Me [ 25th; 75th percentiles] 5.2 [3.8 – 5.5] 3.95 [2.4; 5.1] Leukocytes, × 10 9 /µL, Me [25th; 75th percentiles] 16 [12; 18] 25 [18; 40
Slide 21: SLE: Quality-of-Life Improvements in Patients with SLE Flares
21 SLE: Quality - of - Life Improvements in Patients with SLE Flares After The Course of Procedures Before Improvement in Key Indicator Lupus QoL 76.6 [51.6; 92.2] 57.8 [42.2; 67.2] Physical Health ( ↑ = Improvement) 87.5 [66.7; 91.7] 58.3 [41.7; 70.8] Pain ( ↑ = Improvement) 54.2 [16.7; 83.3] 58.3
Slide 22: Upcoming Pivotal Multicenter Study in EU and Hong Kong for SLE
22 Upcoming Pivotal Multicenter Study in EU and Hong Kong for Treatment of SLE Study Design Number of Subjects: up to 110 with active SLE, SLEDAI - 2K score ≥ 8 Randomized: 1:1 Treatment: SoC or SoC + NucleoCapture ® Primary Effectiveness Endpoint: Proportion of participants achieving a SLE Responde
Slide 23: Sustained cfDNA Reduction and Metabolic Recovery in Discarded Human Livers
23 Demonstrated Sustained cfDNA Reduction and Metabolic Recovery in Discarded Human Livers Eight discarded extended - criteria donor human livers underwent 12 hours of OrganOx metra ® NMP with NucleoCapture , followed by six hours of whole - blood reperfusion modeling ~84% Reduction in Circulating N
Slide 24: DNase Improves In Vivo Efficacy of CAR T Cells
24 DNase Improves In Vivo Efficacy of CAR T Cells Mice treated by CAR19 T cells in combination with DNase demonstrate improved survival and primary tumor clearance in leukemia and lymphoma models with improved CAR19 T cells expansion and persistence DNase survival benefit in mouse model of human lym
Slide 25: Investigator-Initiated Study in Large B-Cell Lymphoma
25 Investigator - Initiated Study in Large B - Cell Lymphoma Anticipated Development Path Q2 2027 Q2 2028 Q3 2028 Primary Efficacy Readouts Secondary Efficacy Readouts Initiate US Phase 2 Study with Potential Partner Q2 2027 Completion of Enrollment Study Design CRR (complete response rate) at 1 mon
Xenetic Biosciences — Merger or Acquisition (September 2026) on 6ix